Revelation Biosciences Inc (REVB) - Total Liabilities
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has total liabilities worth $2.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Revelation Biosciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Revelation Biosciences Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Revelation Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Revelation Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global IBO Group Ltd
NASDAQ:GIBO
|
USA | $27.64 Million |
|
Impera Capital S.A.
WAR:IMP
|
Poland | zł702.00K |
|
FiscalNote Holdings Inc.
NYSE:NOTE
|
USA | $188.64 Million |
|
StageZero Life Sciences Ltd
TO:SZLS
|
Canada | CA$11.71 Million |
|
Hiremii Ltd
AU:HMI
|
Australia | AU$4.74 Million |
|
Era Mandiri Cemerlang Tbk PT
JK:IKAN
|
Indonesia | Rp54.14 Billion |
|
EPRCOMUNICAZIONE S.P.A.
F:J3P
|
Germany | €4.56 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Revelation Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see REVB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revelation Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revelation Biosciences Inc (2016–2025)
The table below shows the annual total liabilities of Revelation Biosciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.72 Million | +42.24% |
| 2024-12-31 | $1.91 Million | -65.61% |
| 2023-12-31 | $5.56 Million | +25.03% |
| 2022-12-31 | $4.45 Million | +107.83% |
| 2021-12-31 | $2.14 Million | +77.18% |
| 2020-12-31 | $1.21 Million | +4494.53% |
| 2019-12-31 | $26.31K | -100.00% |
| 2018-12-31 | $2.19 Billion | +14.64% |
| 2017-12-31 | $1.91 Billion | +10.72% |
| 2016-12-31 | $1.73 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more